Cabozantinib for Advanced Urothelial Cancer

计划入组 69 人 · 首次发布于 2012 年 9 月 20 日

Improve Checkpoint-blockade Response in Advanced Urothelial Cancer

计划入组 53 人 · 首次发布于 2019 年 3 月 12 日

Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer

计划入组 64 人 · 首次发布于 2022 年 10 月 31 日

Quadruplex Oligonucleotides (Advanced Cancer Therapeutics)

Enfortumab vedotin(Padcev)

Rx

Retpamir (Advanced Medical Projects)

ADVANCED BIONICS

France

ADVANCED SCANNERS, INC.

United States

Advanced Bionics AG

Switzerland

Flare Therapeutics Initiates Phase 1B Trial of First-in-Class PPARG Inhibitor FX-909 for Advanced Urothelial Cancer

PADCEV-KEYTRUDA Combination Shows Sustained Survival Benefit in Advanced Urothelial Cancer Trial

Flare Therapeutics Reports Promising Phase 1A Results for First-in-Class PPARG Inhibitor FX-909 in Advanced Urothelial Cancer